Clin Mol Hepatol.
2024 Oct;30(4):970-973. 10.3350/cmh.2024.0280.
Dipeptidyl peptidase-4 inhibitors are associated with improved survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy: Letter to the editor on “Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?”
- Affiliations
-
- 1Medical Data Analytics Centre, The Chinese University of Hong Kong, Hong Kong
- 2Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
- 3Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia
- KMID: 2560099
- DOI: http://doi.org/10.3350/cmh.2024.0280
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?
- Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome
- Emerging Safety Issues of Dipeptidyl Peptidase-4 Inhibitors and Sodium Glucose Cotransporter 2 Inhibitors: How to Interpret and Apply in Clinical Practice
- Novel Therapies for Type 2 Diabetes Mellitus
- Treatment options after sorafenib failure in patients with hepatocellular carcinoma
